CX-157 is primarily investigated for its potential therapeutic applications in the field of neuroscience, particularly in the treatment of mood disorders such as depression. It functions as a selective and reversible monoamine oxidase inhibitor (MAOI), specifically targeting MAO-A, which is involved in the breakdown of neurotransmitters like serotonin, norepinephrine, and dopamine. By inhibiting MAO-A, CX-157 helps increase the levels of these neurotransmitters in the brain, which can improve mood and alleviate symptoms of depression. Its reversible nature reduces the risk of dietary restrictions and side effects commonly associated with traditional MAOIs, making it a promising candidate for safer and more effective antidepressant therapies. Clinical studies are ongoing to further evaluate its efficacy and safety in treating mental health conditions.